The Pfizer-BioNTech COVID-19 vaccine is administered to a personal support worker at the Ottawa Hospital, on December 15, 2020.
The authorisation, as per the ordinary approvals procedure, comes after a rolling submission of data and the totality of scientific evidence submitted by Moderna.
Last month, the Swiss federal government increased its confirmed order commitment from 4.5 to 7.5 million of Moderna's Covid-19 vaccine doses.
The company noted that the first deliveries should commence in Switzerland next week.
On January 11th, Swissmedic granted its authorisation to the Covid vaccine manufactured by the USA company Moderna.
"Switzerland has played a critical role in Moderna's history since our early days and it means a lot to us that we can now provide a highly effective vaccine to help protect the citizens of Switzerland".
The vaccine so far holds authorisation in the US, Canada, Israel, the European Union and the UK.
The United States, which has already administered more than 10 million doses, and president-elect Joe Biden says he wants 100 million doses given out in his first 100 days in office.
More than 2.7 million doses are expected to be distributed across the country over the next seven weeks, with distribution ramping up in February.
Projections show there will be about 500 COVID-19 patients in intensive care by January and potentially more than 1,000 by February in more severe scenarios.
Almost 65,000 doses of the Moderna vaccine arrived in Germany on Monday and were being kept at a military facility in Quakenbrueck in the west of the country.
It is presently in Phase I / II clinical studies and the company anticipates reporting initial safety and immunogenicity data in April.
The vaccine candidate inactivated whole virus particles of SARS-CoV-2 with high S-protein density and two adjuvants, alum and CpG 1018.